title: Early changes of plasma lipids during treatment with atypical antipsychotics.
abstract: Metabolic side effects have been found earlier during treatment with second-generation antipsychotics. Among those disturbances serum lipids are less investigated. We conducted a prospective, open study in schizophrenia patients in order to compare body weight and serum lipids during treatment with amisulpride, ziprasidone, clozapine or olanzapine over a period of 4 weeks. Body mass index, total cholesterol and triglycerides increased in patients treated with clozapine and olanzapine whereas high-density lipoprotein cholesterol decreased in those patients. In patients treated with amisulpride or ziprasidone, we found a decrease in body mass index and total cholesterol whereas high-density lipoprotein cholesterol increased. Our results indicate that treatment with ziprasidone and amisulpride is more favourable than treatment with clozapine and olanzapine with respect to the risk to induce weight gain and hyperlipidaemia. These results are important with regard to the increased risk for cardiovascular complications in patients with schizophrenia.
authors.affiliation: Department of Biological Psychiatry, Medical University Innsbruck, Innsbruck, Austria. maria.rettenbacher@uibk.ac.at
authors.forename: Maria A
authors.initials: MA
authors.lastname: Rettenbacher
authors.forename: Christoph
authors.initials: C
authors.lastname: Ebenbichler
authors.forename: Alex
authors.initials: A
authors.lastname: Hofer
authors.forename: Georg
authors.initials: G
authors.lastname: Kemmler
authors.forename: Susanne
authors.initials: S
authors.lastname: Baumgartner
authors.forename: Monika
authors.initials: M
authors.lastname: Edlinger
authors.forename: Martina
authors.initials: M
authors.lastname: Hummer
authors.forename: Monika
authors.initials: M
authors.lastname: Lechleitner
authors.forename: W Wolfgang
authors.initials: WW
authors.lastname: Fleischhacker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000077582:Amisulpride; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000097:blood / Q000627:therapeutic use; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003024:Clozapine / Q000097:blood / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood*; D008875:Middle Aged; D000077152:Olanzapine; D010879:Piperazines / Q000097:blood / Q000627:therapeutic use; D011446:Prospective Studies; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D013469:Sulpiride / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D013844:Thiazoles / Q000097:blood / Q000627:therapeutic use; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D014150:Antipsychotic Agents; D008055:Lipids; D010879:Piperazines; D013844:Thiazoles; D014280:Triglycerides; D001569:Benzodiazepines; C092292:ziprasidone; D013469:Sulpiride; D000077582:Amisulpride; D002784:Cholesterol; D003024:Clozapine; D000077152:Olanzapine